Dealing with red, itchy eyelids? The culprit could be a common mite. This article is sponsored by XDEMVY. Dr. Watson is a ...

This article highlights clinical and economic factors associated with Demodex blepharitis as well as diagnostic complexities, limitations of traditional therapies, the safety and efficacy of the 1 ...

An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment. Eric D. Donnenfeld, MD; underscores the ...

Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Tarsus Pharmaceuticals (TARS – Research Report). The ...

Tarsus Pharmaceuticals, which has more than 100 of its 331 employees in Orange County, has plans to double its office space ...

This follows a successful 2024 for Tarsus, highlighted by the strong launch of XDEMVY, a treatment for Demodex blepharitis, generating over $113 million in sales. Tarsus is also pursuing ...

Position Trading Today, the company sells one drug that could, potentially, treat 25 million people in the U.S. with Demodex blepharitis, a condition that occurs when mites build up in the eyelashes.

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...

Groundbreaking data from the Ersa and Rhea clinical trials for the treatment of Demodex blepharitis (DB) in patients with Meibomian Gland Disease (MGD) further underscore the utility of XDEMVY broadly ...

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...